MedTrace Logo

Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis

NCT06443658 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-07-03

No results posted yet for this study

Summary

Bronchiectasis is a chronic bronchial disease in which the usual capacity to remove secretions does not function correctly, causing mucus retention that leads to chronic infection. As with all infections, the use of antibiotics and puss removal are essential treatment elements. Physiotherapeutic techniques are used to assist in the removal of secretions, although these are time-consuming practices that need to be much better studied and which patients often do not continue practicing diligently. A physiotherapeutic technique called (Slow prolonged expiration in lateral decubitus) ELTGOL has been shown to be somewhat effective but as the mucus is viscous in this disorder, it can be difficult to get it to move. It is thought that saline solution inhalations may reduce mucus viscosity and could help to ease expectoration, facilitating the removal of the mucus by the physiotherapeutic technique. This project aims to test this hypothesis, which if true could represent an advance in the treatment of this severely debilitating disease.

Conditions

  • Bronchiectasis Adult

Interventions

OTHER

Hypertonic saline

Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique

DRUG

Isotonic saline

Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique

OTHER

ELTGOL

Patients from control group will perform the ELTGOL technique twice-daily

Sponsors & Collaborators

  • University Hospital of Girona Dr. Josep Trueta

    collaborator NETWORK

  • Germans Trias i Pujol Hospital

    collaborator OTHER

  • Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

    lead OTHER

Principal Investigators

  • Montserrat Vendrell, PhD MD · University Hospital of Girona Dr. Josep Trueta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2027-02-28
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06443658 on ClinicalTrials.gov